A landmark 1993 paper cloning the human GLP-1 receptor and identifying exendin-4 as its agonist laid the foundation for three decades of research leading to today's breakthrough obesity and diabetes therapies.
30 yearsfrom receptor cloning to breakthrough obesity therapy
What the researchers found
The 1993 cloning of the human GLP-1 receptor and identification of exendin-4 as its agonist established the molecular foundation for all subsequent GLP-1R drug development.
Why it matters
Understanding the origins of GLP-1 receptor biology provides essential context for the current obesity treatment revolution and highlights how basic science discovery translates into life-changing therapies decades later.
The numbers in context
GLP-1R is a class B G protein-coupled receptor. Exendin-4(1-39) was identified as a potent agonist. Original paper published in Diabetes, 1993.
How the study worked
Historical perspective and review article revisiting the original 1993 Diabetes paper by Thorens et al., tracing its influence across multiple research disciplines over three decades.
Who was studied
Historical review of GLP-1 receptor science
What this study cannot tell us
Perspective article rather than primary research; necessarily selective in coverage of three decades of research; focused on GLP-1R biology without comprehensive comparison to other emerging targets.
How to read the evidence
Strong as a historical review, comprehensively covering the foundational science behind an established drug class.
When this study was published
Published in 2024, providing a timely retrospective as GLP-1R agonists reach peak clinical and public attention.
The bigger picture
The GLP-1 receptor story is one of the most successful examples of bench-to-bedside translation in modern medicine — from a single receptor cloning paper to a multi-billion dollar drug class that is reshaping obesity and diabetes treatment worldwide.
Questions still open
- What remaining GLP-1R biology questions could unlock the next generation of even more effective therapies?
- How do structural insights into GLP-1R conformations inform the design of biased agonists?
- Can GLP-1R genetics predict individual treatment response?
Common questions
Where did GLP-1 medications originally come from?
Why are GLP-1 medications considered such a breakthrough?
Read the original research
Building the Glucagon-Like Peptide-1 Receptor Brick by Brick: Revisiting a 1993 Diabetes Classic by Thorens et al.
Diabetes, 73(7), 1027-1031
Citation
Thorens, Bernard; Hodson, David J. (2024). Building the Glucagon-Like Peptide-1 Receptor Brick by Brick: Revisiting a 1993 Diabetes Classic by Thorens et al.. Diabetes, 73(7), 1027-1031. https://doi.org/10.2337/dbi24-0025